Abstract. To determine the biological roles of cell surface glycosylation, we modified the surface glycosylation of human malignant lymphoma cell lines using glycosylation inhibitors. The O-glycosylation inhibitor, benzyl-α-GalNAc (BZ) enhanced the fibronectin adhesion of HBL-8 cells, a human Burkitt's lymphoma cell line, and of H-ALCL cells, a human anaplastic large cell lymphoma cell line, both of which were established in our laboratory. The N-glycosylation inhibitor, tunicamycin (TM) inhibited the surface expression of Phaseolus vulgaris leukoagglutinating (L-PHA) lectin-and Canavalia ensiformis (ConA) lectinreactive oligosaccharides in the HBL-8 cell line. Assay of the adhesion of HBL-8 cells to fibronectin showed that fibronectin adhesion is mediated by the integrin very late antigen (VLA)-4 and that not only BZ but also TM treatment enhanced HBL-8 cell adhesion to fibronectin. Furthermore, although BZ treatment also enhanced H-ALCL cell adhesion to fibronectin, this effect was not mediated by VLA-5 or the RGD sequence of fibronectin. We also showed that H-ALCL cell adhesion to galectin-3 was enhanced by pre-treatment with neuraminidase, which cleaves cell surface sialic acid. Additionally, H-ALCL cell adhesion to galectin-3 was inhibited by pre-treatment with the RGD peptide suggesting that cell adhesion to galectin-3 is mediated by integrin (VLA-5). Furthermore, H-ALCL cell invasion of galectin-1 and galectin-3 was inhibited by pre-treatment with the RGD peptide. Therefore, cell adhesion to and invasion of galectin-1 and galectin-3 are integrin-dependent. In addition to these findings, cell adhesion to galectin-3 was markedly inhibited by treatment with β-lactose compared to treatment with sucrose.
Introduction
Glycosylation of human malignant lymphoma cells is known to be closely associated with the patient clinical outcome (1, 2) . We speculated that cell surface glycans may play an important role in lymphoma cell behavior. In a recent study we showed that loss of cell surface Peanut agglutinin (PNA) reactive oligosaccharides is closely associated with a poor prognosis of patients with Burkitt's lymphoma (3) . Cell surface O-linked oligosaccharides play an important role in cell adhesion (4) (5) (6) or galectin-induced cell death (7) .
We also previously showed that loss of cell surface L-PHA reactive oligosaccharides or ConA reactive oligosaccharides is also closely associated with a poor prognosis of patients with Burkitt's lymphoma (3) . Several studies have suggested that remodeling of the cell surface N-linked oligosaccharides of various cell lines can regulate cell adhesive properties to the extracellular matrix (ECM) (8, 9) . We previously reported that alteration of N-linked oligosaccharides by treatment of cells with the glycosylation inhibitor swainsonine (SW) resulted in enhancement of lymphoma cell adhesion to galectin-1 (10) .
In the present study we analyzed whether treatment with the O-glycosylation inhibitor BZ, the N-glycosylation inhibitors, swainsonine (SW) or TM, or with an enzyme that cleaves sialic acid, neuraminidase, might influence adhesion to the ECM of cells of a Burkitt's lymphoma and an anaplastic large cell lymphoma cell line. The biological significance of cell surface oligosaccharides associated with β1-integrin mediated lymphoma cell adhesion to the ECM is discussed.
Materials and methods
Cell lines. The HBL-8 cell line was established in our laboratory from a patient who had Burkitt's lymphoma (10) . The human anaplastic large cell lymphoma cell line, H-ALCL, was also established in our laboratory from a patient. HBL-8 cells (clone, 3G3) and H-ALCL cells were grown in RPMI-1640 culture medium containing 15% fetal calf serum, under 5% CO 2 at 37˚C. Flow cytometric analysis indicated that the H-ALCL cell line expresses the galectin-1 receptors, CD45RA (leukocyte common antigen, LCA) and CD45RO (UCHL-1) (data not shown). The use of these two cell lines that were derived from patients was approved by the Bioethics Committee of Fukushima Medical University. The informed consent was obtained by disclosure of research concept on Web site Home Page in Fukushima Medical University.
Reagents. The biotinylated lectins, Arachis hypogaea (PNA; BA-2301-2), Phaseolus vulgaris (L-PHA; BA-1801-2), Canavalia ensiformis (ConA; BA-1104-5 and Helix Pomatia (HPA; BA-3601-1) were purchased from EY Laboratories (San Mateo, CA, USA). Anti-VLA-1 antibody, clone 5E8D9, was from Upstate Biotechnology (NY, USA). Anti-VLA-2 antibody, clone Ak-7, and anti-VLA-3 antibody, clone C3 II.1 were from BD Pharmingen (USA). Anti-VLA-4 antibody, clone HP2/1, was from Immunotech, a Beckman Coulter Co. (France). Anti-VLA-5 antibody, clone NkI-SAM-1, was from Chemicon International (USA). Anti-CD45 antibody (leukocyte common antigen, LCA) was from Nichirei, H0408, Japan.
Flow cytometric analysis. In brief, 5x10
5 cells of the HBL-8 3G3 cloned cell line were suspended in 100 µl phosphate-buffered saline (PBS), and incubated with 5 µl biotinylated lectins or anti-VLA monoclonal antibodies at 4˚C for 20 min and, then washed twice with PBS. The cells were then incubated with 5 µl avidin-FITC (Vector Laboratories, Inc., Burlingame, CA, USA) at 4˚C for 20 min or with 5 µl fluorescein conjugated anti-mouse immunoglobulin (#AMI 4408, BioSource International Inc., CA, USA) at 4˚C for 20 min, and were subsequently washed twice with PBS, following which fluorescence intensity was analyzed using a FACScan.
For inhibition of O-linked oligosaccharides, 5x10 6 HBL-8 3G3 cloned cells were incubated at 37˚C in 20 ml RPMI-1640 containing 15% FCS with or without 2 mM BZ for 48 h before flow cytometric analysis using biotinylated HPA lectin. For inhibition of N-glycans, 1x10 7 HBL-8 3G3 cloned cells were incubated at 37˚C in 20 ml RPMI-1640 containing 15% FCS with or without 0.1 µg/ml SW or with or without 1.0 µg/ml TM for 24 h before flow cytometric analysis using biotinylated L-PHA, ConA or PNA lectins.
Cell adhesion assay. The 96-well tissue culture plates were coated with the matrix protein fibronectin (4305-FN, R&D Systems, USA: 0.5, 1.0 and 1.5 µg/well), human recombinant galectin-1 (10 µg/well, ATGP0385, ATGen Co. Ltd., USA) and galectin-3 (2 µg/well, PROSPEC, CYT-606, Funakoshi, Japan), and were dried at room temperature overnight. Each well was filled with 100 µl PBS solution and the PBS was then removed by aspiration. Each well was filled with RPMI-1640 culture medium containing 15% BSA and 15% FCS, and was cultured at 37˚C for 60 min. After aspiration of the medium, HBL-8 or H-ALCL cells (100 µl from the cell density at 1x10 6 /2 ml) were added to each well and were incubated at 37˚C for 1 or 2 h. After aspiration of the medium, PBS solution was added to each well and the PBS was then aspirated to remove non-adhered cells. Subsequently, 100 µl of 3.7% formaldehyde was added to each well to fix the adhered cells, and was incubated at RT for 40 min. After aspiration of the formaldehyde, 100 µl of 0.1% crystal violet was added to each well and the plates were incubated at RT for 40 min. After aspiration of the crystal violet, 200 µl of PBS was added to each well and then removed by aspiration. Subsequently, 100 µl of 10% acetic acid was added to each well and the absorbance at 570-655 or 570 nm was determined using an ELISA plate reader (iMark™, Microplate Reader, Bio-Rad, Hercules, CA, USA) (10) . The capacity of the cells to adhere to the extracellular matrix was evaluated by analysis of the absorbance in tested wells.
To confirm the β1-integrin-dependency of cell adhesion, inhibition assays were performed by pre-incubation of the cells with 2 µg isotype control Ab/100 µl PBS for 1 h (purified mouse IgG, κ isotype, cat no. 555746, BD Pharmingen, Japan), 2 µg anti-VLA-4 antibody/100 µl PBS for 1 h (HP2/1, no. 0764, Immunotech, A Coulter Co.), 2 µg ant-VLA-5 antibody/100 µl PBS for 1 h (MAB1986, Chemicon), 1 µg/µl Fibronectin CS-1 peptide for 1 h (GWB-B6016B, GenWay Biotech. Inc. San Diego, CA, USA) or with 1 µg/µl Fibronectin RGD peptide for 1 h (A8052; Sigma, Japan) prior to the fibronectin or galectin adhesion assay.
For inhibition of O-linked oligosaccharides, 5x10 6 HBL-8 3G3 cloned cells were incubated at 37˚C in 20 ml RPMI-1640 containing 15% FCS with or without 2 mM BZ for 48 h before the adhesion assay. For inhibition of N-glycans, 1x10 7 HBL-8 3G3 cloned cells were incubated at 37˚C in 20 ml RPMI-1640 containing 15% FCS with or without 0.1 µg/ml SW for 24 h before the adhesion assay; or 5x10 6 HBL-8 3G3 cloned cells were incubated at 37˚C in 20 ml RPMI-1640 containing 15% FCS with or without 1.0 µg/ml TM for 24 h before the adhesion assay.
To analyze the role of cell surface sialic acid in cell adhesion to galectin, H-ALCL cells were pre-treated with or without 0.2 U/ml neuraminidase from Arthrobacter ureafaciens (no. 10269611001, Roche, Germany) at 37˚C for 30 min before the adhesion/invasion assay. To analyze the geta-galactose dependency, the cell adhesion assay to galectins was performed with 0.1 M β-lactose, and in the control, with 0.1 M sucrose.
Invasion assay. The invasion assay (haptotaxis) was performed as reported (12) with several modifications. The 24-well culture plate was filled with 600 µl the culture medium RPMI-1640 containing 15% BSA 15% FCS. The lower surfaces of the membranes of transwell chamber, chemotaxicell (krabo, Japan) witrh 8-µm pore membrane were coated with 10 µl galectin-1, galectin-3 or galectin-8 and dried at RT. Then coated chemotaxicells were inserted into each well. In total 100 µl of 3x10 6 /ml H-ALCL cells was inserted into each chemotaxicell and incubated at 37˚C for 24 h. After incubation, the invaded cells in the lower surfaces of each well were counted by trypanblue exclusion methods. The cell count was performed using triplicate wells (n=3). To evaluation of effect of AZA1, the cells were pre-incubated with 25 µM AZA1, for 1 h.
Statistical analysis. The p-values in the experimental results were calculated based on Student's t-test. p<0.05 was considered statistically significant. Data analysis was performed using Microsoft Office Excel 2007.
Results
Cell surface expression of VLA integrins. Flow cytometric analysis indicated that the integrins VLA-1, -3 and -4 were expressed on the cell surface of HBL-8 3G3 cloned cells, but that VLA-2 and -5 were not expressed (Fig. 1) . Previous immunohistochemical findings showed that the H-ALCL cells express VLA-5, but not VLA-4 (11).
Effect of alteration of cell surface O-and N-glycans on cell lectin reactivity.
Flow cytometric analysis of HBL-8 3G3 cells indicated that the HPA lectin reactivity of the cells increased after inhibition of O-glycosylation with BZ treatment (Fig. 2A) . Following inhibition of N-glycosylation with SW treatment the L-PHA reactivity of the cells decreased and the ConA reactivity of the cells increased (Fig. 2B) . On the other hand after inhibition of N-glycosylation with TM treatment both the L-PHA reactivity and the ConA reactivity of the cells decreased (Fig. 2C) . Our recent report showed that L-PHA reactivity of H-ALCL cells also decreased after TM treatment non-treated and SW-treated cells (Fig. 3C) . On the other hand treatment with TM enhanced HBL-8 3G3 cell adhesion to fibronectin compared to non-treated cells (Fig. 3D) . Thus, alteration of cell surface glycosylation modulates cell adhesion to fibronectin. The enhancement of H-ALCL adhesion to fibronectin by BZ was not mediated by the integrin VLA-5, or by CS-1 or RGD protein sequences (Fig. 4) .
Effect of alteration of cell surface glycosylation on H-ALCL cell adhesion to galectins. H-ALCL cells also adhered to
galectin-3 and this adhesion to galectin-3 was enhanced by cleavage of cell surface sialic acids by pre-treatment with neuraminidase (Fig. 5A) . Furthermore, H-ALCL cell adhesion to galectin-3 was inhibited by RGD peptide pre-treatment (Fig. 5B) , with serum-free medium. The ability of H-ALCL cells to invade galectin-1 and galectin-3 was markedly inhibited by pre-incubation with the RGD peptide, indicating that this invasion was dependent on the RGD sequence (Fig. 6A) .
Further inhibition experiments showed that inhibition of H-ALCL cell adhesion to galectin-3 by β-lactose was much higher compared to inhibition by sucrose suggesting that H-ALCL cell adhesion to galectin-3 might be mediated by β-galactose on the cell surface (Fig. 6B) . Potential involvement of small GTP proteins in the galectin invasion of H-ALCL cells. Immunohistochemical analysis showed that Rac 1 and Cdc42 proteins were expressed in the cytoplasm of H-ALCL cells (Fig. 7) . Our previous immunohistochemical analysis showed that Rho is also expressed in the cytoplasm of H-ALCL cells and that the Rho inhibitor, C3-transferase, markedly inhibited H-ALCL invasion of galectins (12). Pre-incubation of H-ALCL cells with AZA1, an inhibitor of Rac 1 and Cdc42, also significantly inhibited cell invasion of galectin-1 and galectin-3 (Fig. 8 ). The combined above data suggested that the small GTPases Rho, Rac 1 and Cdc42 are involved in H-ALCL invasion to galectin.
Discussion
The ability of cells to adhere to the ECM is known to be closely associated with the metastatic capacity of malignant tumor cells. Alteration of cell surface glycans can modulate the metastatic rate to distant organs. In the present study, using glycoengineering methods we showed a biological role of the surface glycans of malignant lymphoma cells in cell adhesion and cell invasion to extracellular matrix.
The presence of O-glycans and HPA reactive oligosaccharides was demonstrated on HBL-8 cells using flow cytometric analysis. BZ enhanced the expression of HPA reactive oligosaccharides i.e., GalNAc residues. Adhesion of HBL-8 cells to fibronectin was mediated by the VLA-4 adhesion molecule. This fibronectin adhesion of HBL-8 was enhanced by treatment with BZ. It was unclear whether the VLA-4 mediated cell adhesion was directly modified by administration of BZ and we speculate that the effect of BZ may be mediated by a GalNAc epitope that affects the interactions between VLA-4 and fibronectin. Such a candidate GalNAc epitope would be a mucin type epitope, or O-linked oligosaccharides. It is known that O-linked oligosaccharides can influence cell adhesive properties (4, 5, 13) . BZ treatment also enhanced the adhesion of H-ALCL cells to fibronectin. BZ treatment is known to remove sialic acid which is linked to the terminal residue of glycans. Therefore, desialylation of O-glycans by BZ may also enhance cell adhesion to fibronectin. Our present data obtained using H-ALCL cells indicated that this effect is independent of VLA-5 and the RGD sequence of fibronectin. Therefore, the sialic acid on O-glycans may regulate cell adhesion to fibronectin independently of integrins. Previous reports have suggested that desialylation of integrin upregulates cell adhesion to fibronectin (14) . On the other hand α-2,6 sialic acid has been reported to be required for cell adhesion to fibronectin (15) . In pancreatic carcinoma cells, α-2,6 sialic acid is required for tumor cell adhesion to the ECM (16) . Based on these findings it appears that there is a difference in the regulation of cell adhesion to the ECM by sialylation among various cell types. Further study will be required to clarify the detailed mechanisms by which sialic acid regulates cell adhesion to the ECM. CD45 is a candidate receptor for galectin-1 and -3 (17) . However, recent data suggest that integrin is also a candidate galectin-3 receptor (18) . In our present data, H-ALCL cell adhesion to galectin-3 was inhibited by pretreatment with the RGD peptide suggesting that cell adhesion to galectin-3 was mediated by integrin (VLA-5). Therefore, sialylation may regulate cell adhesion to galectin-3 in an integrin-dependent manner and integrin may act as a galectin receptor in cell adhesion to galectins (Fig. 9 ). In this model cell adhesion to galectin through integrins would activate intrinsic signals leading to the activation of Rho, Rac 1 and Ccd42, and resulting in rearrangement of the cytoskeleton. These events act as a driving force of cell migration. Therefore, sialic acid may regulate lymphoma cell invasion to galectin through galectin-integrin interaction, subsequently inducing Rho family activation and rearrangement of the cytoskeleton. These phenomena may be associated with lymphoma cell invasion and metastasis.
N-linked oligosaccharides are known to be transferred onto asparagine residues of proteins from a donor substrate, dolichol-phosphate-oligosaccharide, in the endoplasmic reticulum (19) . Deglycosylation of glycoproteins that is reflected by a decrease in L-PHA and ConA lectin reactivity may be related to dysfunction of this oligosaccharide transfer to proteins, which is catalyzed by the enzyme oligosaccharyltransferase in the endoplasmic reticulum. The N-glycan inhibitor, SW can inhibit complex type N-glycans, resulting in the expression of hybrid type N-glycans. On the other hand TM can inhibit both complex and hybrid type N-glycan expression. Our data showed that SW cannot enhance cell adhesion to fibronectin, whereas TM can. Therefore, differences in the detail of the N-glycan structures resulting from SW and TM treatments can influence cell adhesion to FN. Not only O-glycans, but also N-glycans may regulate HBL-8 and H-ALCL cell adhesion to fibronectin. Some previous studies have suggested that alteration of the N-glycosylation of β-1 integrins may modulate the ability of cells to adhere to the ECM (20) . In addition to this, it was suggested that VLA-4 expression may be closely related to the ability of a tumor to metastasize to distant organs in an animal model (21) . Therefore, cell surface N-glycans may modulate metastatic capacity by modulation of VLA-4 function in lymphoma cells.
In a previous report we showed that L-PHA reactive N-linked oligosaccharide on the lymphoma cell surface is closely associated with clinical behavior of diffuse large B cell lymphoma (DLBCL) cases (1, 2) . Loss of L-PHA reactive N-glycans on the cell surface is correlated to a poor prognosis of DLBCL. In the present study TM treatment resulted in enhancement of HBL-8 3G3 lymphoma cell adhesion to fibronectin or in the recent study, inhibition of H-ALCL cell adhesion to fibronectin and laminin (11) . N-glycan bidirectionally regulates cell adhesion to fibronectin suggesting that alteration of N-glycans affects cell adhesion to the ECM resulting in modulation of the biological behavior of lymphoma cells. Previous reports showed that TM treatment modulates cell surface glycosylation expression, resulting in alteration of cell adhesion to the ECM (22) , and that alteration of cell surface glycosylation affects cell to cell adhesion or cell-matrix interaction in several tumor cell lines (22, (23) (24) (25) (26) 27, 28) . These findings and our present data may provide a new scientific area of study of tumor cell biology that is focused on the regulation of cell adhesion to the ECM by glycosylation.
GTPases are known to include Rac 1, Cdc42 and Rho. Rac 1 forms lamellipodia, Cdc42 forms filopodia, and Rho forms stress fibers, and these molecules are known to be associated with cancer progression (29) . The function of these molecules is associated with cell motility of lymphoma cells that is mediated through galectins in the stroma. Furthermore, sialic acid on the cell surface may regulate cell adhesion to galectins that is mediated by integrins. Sialic acid is adequately regulated on cell adhesion to galectin resulting in facilitation of cell motility, and subsequently enhances cell motility resulting in more aggressive tumor behavior and metastasis. In the present data, cell adhesion to galectin-3 was inhibited by cell surface sialylation suggesting that cell surface sialic acid may regulate cell adhesion to galectins. In terms of cell surface glycosylation, especially of sialylation, we speculate that sialylation enhances Rho GTPase family induced cell invasive capacity and may result in a worse prognosis of the patients. Our present data showed that desialylation enhanced cell adhesion to galectin and inhibited cell invasion to galectin (12) , suggesting that the effect of desialylation on cell invasion of galectin is the opposite to the effect of the Rho GTPase family on cell invasion.
In conclusion, cell surface sialylation appeared to be a candidate molecule for the regulation of cell adhesion, and the present data may provide a new scientific focus for lymphoma glycobiology.
